The discovery of novel rare pathogenic variants of CFTR, as well as their experimental functional characterization, are mandatory to ameliorate our diagnostic, prognostic and, in the era of CF personalized medicine, therapeutic ability. This evidence concerns the gene CFTR and cystic fibrosis.